An epigenetic pathway regulates MHC-II expression and function in B cell lymphoma models
Journal of Clinical Investigation · 2025
DOI: 10.1172/jci179703 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, 2025. Verfasst von Te Zhang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Molecular Genetics and. Hauptthemen laut MEDLINE: Epigenesis, Genetic, Lymphoma, B-Cell, Gene Expression Regulation, Neoplastic, Histocompatibility Antigens Class II. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, National Institutes of Health, American Cancer Society.
Abstract (Originalsprache)
Mutations or homozygous deletions of MHC class II (MHC-II) genes are commonly found in B cell lymphomas that develop in immune-privileged sites and have been associated with patient survival. However, the mechanisms regulating MHC-II expression, particularly through genetic and epigenetic factors, are not yet fully understood. In this study, we identified a key signaling pathway involving the histone H2AK119 deubiquitinase BRCA1 associated protein 1 (BAP1), the interferon regulatory factor interferon regulatory factor 1 (IRF1), and the MHC-II transactivator class II transactivator (CIITA), which directly activates MHC-II gene expression. Disruption of the BAP1/IRF1/CIITA axis leads to a functional attenuation of MHC-II expression and MHC-II–dependent immune cell infiltration, leading to accelerated tumor growth in immunocompetent mice. Additionally, we demonstrated that pharmacological inhibition of polycomb repressive complex 1 (PRC1) — which deposits histone H2K119Ub and opposes BAP1 activity — can restore MHC-II gene expression in BAP1-deficient B cell lymphoma cells. These findings suggest that BAP1 may function as a tumor suppressor by regulating the tumor microenvironment and immune response. Our study also establishes the rationale for therapeutic strategies to restore tumor-specific MHC-II expression and enhance immunotherapy outcomes at epigenetic levels in B cell lymphoma treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biochemistry and Molecular Genetics and.
- Simpson Querrey Center for Epigenetics, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
Förderung
- NIGMS NIH HHS
- National Institutes of Health
- American Cancer Society
- U.S. Department of Defense
Zitieren
APA
Zhang, T., Beytullahoglu, O., Tulaiha, R., Luvisotto, A., Szczepanski, A., Tsuboyama, N., Zhao, Z., & Wang, L. (2025). An epigenetic pathway regulates MHC-II expression and function in B cell lymphoma models. Journal of Clinical Investigation. https://doi.org/10.1172/jci179703
Vancouver
Zhang T, Beytullahoglu O, Tulaiha R, Luvisotto A, Szczepanski A, Tsuboyama N, et al. An epigenetic pathway regulates MHC-II expression and function in B cell lymphoma models. Journal of Clinical Investigation. 2025. doi:10.1172/jci179703
BibTeX
@article{Zhang2025,
author = {Zhang, Te and Beytullahoglu, Oguzhan and Tulaiha, Rima and Luvisotto, Amanda and Szczepanski, Aileen and Tsuboyama, Natsumi and Zhao, Zibo and Wang, Lu},
title = {An epigenetic pathway regulates MHC-II expression and function in B cell lymphoma models},
journal = {Journal of Clinical Investigation},
year = {2025},
doi = {10.1172/jci179703}
}
EUVIMED